|
|
Blood, 1 February 2004, Vol. 103, No. 3, pp. 1069-1077.
Prepublished online as a Blood First Edition Paper on October 2, 2003; DOI 10.1182/blood-2003-06-1930.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice
Hitendra Singh Chand,
Xin Du,
Duan Ma,
Hector David Inzunza,
Shintaro Kamei,
Donald Foster,
Steven Brodie, and
Walter Kisiel
From the Departments of Pathology and Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque; and ZymoGenetics Inc, Seattle, WA.
Human tissue factor pathway inhibitor-2 (TFPI-2) is a matrix-associated Kunitz inhibitor that inhibits the plasmin- and trypsin-mediated activation of zymogen matrix metalloproteinases involved in tumor progression, invasion, and metastasis. To directly assess its role in tumor growth and metastasis in vivo, we stably transfected HT-1080 fibrosarcoma cells expressing either fully active wild-type human TFPI-2 (WT) or inactive R24Q TFPI-2 (QT) and examined their ability to form tumors and metastasize in athymic mice in comparison to mock-transfected cells (MT). MT and QT fibrosarcoma tumors grew 2 to 3 times larger than WT tumors. Tumor metastasis was confined to the lung and was observed in 75% of mice treated with either MT or QT cells, whereas only 42% of mice treated with WT cells developed lung metastases. Real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analyses of each tumor group revealed 3- to 6-fold lower levels of murine vascular endothelial growth factor gene expression in WT tumors in relation to either MT or QT tumors. Comparative tumor gene expression analysis revealed that several human genes implicated in oncogenesis, invasion, metastasis, apoptosis, and angiogenesis had significantly altered levels of expression in WT tumors. Our collective data demonstrate that secretion of inhibitory TFPI-2 by a highly metastatic tumor cell markedly inhibits its growth and metastasis in vivo by regulating pericellular extracellular matrix (ECM) remodeling and angiogenesis. (Blood. 2004;103:1069-1077)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. George, C. S. Gondi, D. H. Dinh, M. Gujrati, and J. S. Rao
Restoration of Tissue Factor Pathway Inhibitor-2 in a Human Glioblastoma Cell Line Triggers Caspase-Mediated Pathway and Apoptosis
Clin. Cancer Res.,
June 15, 2007;
13(12):
3507 - 3517.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ivanciu, R. D. Gerard, H. Tang, F. Lupu, and C. Lupu
Adenovirus-Mediated Expression of Tissue Factor Pathway Inhibitor-2 Inhibits Endothelial Cell Migration and Angiogenesis
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2007;
27(2):
310 - 316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Xu, D. Maiti, W. Kisiel, and E. J. Duh
Tissue Factor Pathway Inhibitor-2 Is Upregulated by Vascular Endothelial Growth Factor and Suppresses Growth Factor-Induced Proliferation of Endothelial Cells
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2006;
26(12):
2819 - 2825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. X. Torres-Collado, W. Kisiel, M. L. Iruela-Arispe, and J. C. Rodriguez-Manzaneque
ADAMTS1 Interacts with, Cleaves, and Modifies the Extracellular Location of the Matrix Inhibitor Tissue Factor Pathway Inhibitor-2
J. Biol. Chem.,
June 30, 2006;
281(26):
17827 - 17837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Schmidt, H. S. Chand, D. Cascio, W. Kisiel, and S. P. Bajaj
Crystal Structure of Kunitz Domain 1 (KD1) of Tissue Factor Pathway Inhibitor-2 in Complex with Trypsin: IMPLICATIONS FOR KD1 SPECIFICITY OF INHIBITION
J. Biol. Chem.,
July 29, 2005;
280(30):
27832 - 27838.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. S. Chand, A. E. Schmidt, S. P. Bajaj, and W. Kisiel
Structure-Function Analysis of the Reactive Site in the First Kunitz-type Domain of Human Tissue Factor Pathway Inhibitor-2
J. Biol. Chem.,
April 23, 2004;
279(17):
17500 - 17507.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
